@article{Sun2026, 
author = {Haijun Sun and Wenyue Yan and Zhanyu Li and Qintian Li and Qilong Du and Li Xu and Wanwei Cao and Junrong Yang and Xilan Yang and Jun Chen and Yuan Mao and Wen Huang},
title = {The Construction and Preclinical Evaluation of Antitumor Activity of a Novel MIgG-OXA ADC in Lung Adenocarcinoma},
year = {2026},
journal = {Oncology Research},
volume = {34},
number = {8},
pages = {21},
keywords = {Melanoma-associated antigen-A1 (MAGE-A1), immunoglobulin G (IgG), oxaliplatin (OXA), antibody-drug conjugates (ADCs)},
url = {https://www.sciopen.com/article/10.32604/or.2026.080413},
doi = {10.32604/or.2026.080413},
abstract = {BackgroundThe melanoma-associated antigen-A1 (MAGE-A1) demonstrates tumor-restricted expression patterns in diverse malignancies, positioning it as an attractive therapeutic target. This investigation aimed to engineer and validate a novel antibody-drug conjugate with oxaliplatin targeting MAGE-Al (MIg-OXA), a novel antibody-drug conjugate targeting MAGE-A1, while assessing its therapeutic potential against MAGE-A1-expressing lung adenocarcinoma through both cellular and animal models.MethodsWe generated a MAGE-A1-specific immunoglobulin G (IgG) antibody (MIgG) and subsequently conjugated it with oxaliplatin (OXA) to produce MIgG-OXA. The conjugate’s binding specificity and cellular uptake were verified through cell-based enzyme-linked immunosorbent assay (ELISA), flow cytometric analysis, and immunofluorescence microscopy. Functional assessments included Cell Counting Kit-8 (CCK-8) viability assays, transwell migration studies, apoptosis detection, and antibody-dependent cell-mediated cytotoxicity (ADCC) evaluation to determine anti-neoplastic activity in cultured cells. Therapeutic efficacy in living organisms was examined using lung adenocarcinoma (LUAD) xenograft-bearing athymic mice.ResultsOur data confirmed successful synthesis and validation of MIgG-OXA, which demonstrated selective recognition of MAGE-A1-expressing LUAD cell populations and facilitated controlled OXA release. When compared to unconjugated OXA, MIgG-OXA displayed enhanced tumor suppression in both cultured LUAD cells and transplanted tumor models.ConclusionThese findings collectively indicate that MIgG-OXA holds substantial promise as a precision therapeutic approach for patients harboring MAGE-A1-positive LUAD.}
}